Prognostic value of ERCC1, RRM1, BRCA1 and SETDB1 in early stage of non-small cell lung cancer

Introduction Nowadays, 40 % of early-stage NSCLC patients relapse in the 2 years following resection, suggesting a mis-staging in this group of patients who are not receiving adjuvant chemotherapy. Although different biomarkers, such as ERCC1 , RRM1 and BRCA1 have been found to present prognostic va...

Full description

Saved in:
Bibliographic Details
Published in:Clinical & translational oncology 2016-08, Vol.18 (8), p.798-804
Main Authors: Lafuente-Sanchis, A., Zúñiga, Á., Galbis, J. M., Cremades, A., Estors, M., Martínez-Hernández, N. J., Carretero, J.
Format: Article
Language:English
Subjects:
Adult
Aged
Biomarkers, Tumor - analysis
BRCA1 Protein - analysis
BRCA1 Protein - biosynthesis
Carcinoma, Non-Small-Cell Lung - metabolism
Carcinoma, Non-Small-Cell Lung - mortality
Carcinoma, Non-Small-Cell Lung - pathology
Disease-Free Survival
DNA-Binding Proteins - analysis
DNA-Binding Proteins - biosynthesis
Endonucleases - analysis
Endonucleases - biosynthesis
Female
Humans
Kaplan-Meier Estimate
Lung Neoplasms - metabolism
Lung Neoplasms - mortality
Lung Neoplasms - pathology
Male
Medicine
Medicine & Public Health
Middle Aged
Neoplasm Recurrence, Local - metabolism
Neoplasm Recurrence, Local - mortality
Neoplasm Recurrence, Local - pathology
Oncology
Prognosis
Proportional Hazards Models
Protein Methyltransferases - analysis
Protein Methyltransferases - biosynthesis
Real-Time Polymerase Chain Reaction
Research Article
Tumor Suppressor Proteins - analysis
Tumor Suppressor Proteins - biosynthesis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction Nowadays, 40 % of early-stage NSCLC patients relapse in the 2 years following resection, suggesting a mis-staging in this group of patients who are not receiving adjuvant chemotherapy. Although different biomarkers, such as ERCC1 , RRM1 and BRCA1 have been found to present prognostic value in advanced NSCLC patients, in early-stage NSCLC patients its relevance remains unclear. Moreover, SETDB1 has been recently proposed as a bona fide oncogene in lung tumourigenesis and related with metastasis. The aim of the present study was to analyze the prognostic value of ERCC1 , RRM1 , BRCA1 and SETDB1 expression levels in NSCLC patients at stage I. Patients and methods ERCC1, RRM1, BRCA1 and SETDB1 expression at mRNA level was analyzed by real-time quantitative RT-PCR in fresh-frozen tumor and normal adjacent lung tissue samples from 64 stage I NSCLC patients. Later, significant association between gene expression levels, clinicopathological characteristics and patient’s disease-free survival was assessed. Results We did not find any statistically significant correlation between gene expression and gender, age, histological type or smoking status. Univariate followed by multivariate Cox analysis showed that higher levels of BRCA1 and SETDB1 expression were significantly associated with shorter disease-free survival in stage I NSCLC patients. Conclusion Our study finds that ERCC1 and RRM1 are not independent prognostic factors of recurrence in stage I NSCLC patients. By contrast, BRCA1 and SETDB1 stand out as the most significant prognostic markers in this group of patients, appearing as promising tools to predict tumor recurrence in early-stage NSCLC patients.
ISSN:1699-048X
1699-3055
DOI:10.1007/s12094-015-1440-6